How much will medical insurance reimburse Crizotinib in 2023?

Crizotinib (Crizotinib) is a targeted therapy drug that is a tyrosine kinase inhibitor. It is primarily used to treat certain types of non-small cell lung cancer (NSCLC), including ALK (Anaplastic Lymphoma Kinase) fusion-positive NSCLC and ROS1 (c-ros Oncogene 1) fusion-positive NSCLC.

Crizotinib is currently on the market in China and is included in medical insurance. Patients can purchase it domestically, and the price is around 6,000~12,000 yuan. Since the price of medical insurance policies varies greatly across regions, please consult your local pharmacy or medical insurance bureau for specific prices. There are original and generic versions of crizotinib available abroad. The original version is mainly Pfizer’s original drug, and the price is around 11,000 yuan. Generic drugs are mainly from Bangladesh and Laos. Due to different pharmaceutical manufacturers and drug specifications, generic drugs cost around 2,700~3,000 yuan. Moreover, the ingredients of foreign original drugs and generic drugs are basically the same as those of domestic drugs.

Crizotinib is a targeted therapy that targets a specific fusion protein. In ALKfusion-positive and ROS1fusion-positive NSCLC patients, abnormal ALK and ROS1 genes lead to protein fusion, forming abnormal fusion proteins that promote tumor growth and spread. Crizotinib can inhibit the activity of these abnormal fusion proteins, thereby slowing the proliferation and growth of tumor cells.

Crizotinib is mainly used to treat ALK fusion-positive NSCLC and ROS1 fusion-positive NSCLC. In these specific types of lung cancer, crizotinib is considered an effective treatment option. Crizotinib is generally available as an oral tablet. Patients should take the medicine at a fixed time every day according to the doctor's prescription and advice. The dosage will be adjusted based on the patient's condition and response to treatment.